February 4 is World Cancer Day—a global initiative led by the Union for International Cancer Control. Patients, families, communities, clinicians, researchers and others are joining together to raise awareness and to act.
Here at Canada’s Michael Smith Genome Sciences Centre at BC Cancer, we are making significant strides in realizing the benefit of genomics in researching, understanding, diagnosing and treating cancer.
Gene expression analysis of pancreatic ductal adenocarcinoma (PDAC) tumours enables clinicians to stratify patients into molecular subgroups and select treatments that are best suited to each type; however, molecular subtyping remains cost-prohibitive and is not yet part of routine cancer care.
Large-scale genome sequencing initiatives frequently rely on datasets provided by different sequencing centres, all of which may employ different laboratory protocols, instruments and analytical methods that may introduce disparities in the data produced. When combining datasets generated at different institutions, how do researchers ensure consistency between datasets?
As researchers work towards establishing whole genome and transcriptome analysis into clinical practice for cancer care, scientists at the GSC continue developing innovative laboratory methods to improve efficiency and accuracy.
Whole genome and transcriptome sequencing uncovers biomarkers predicting response to immune checkpoint inhibitors
The development of immune checkpoint inhibitors (ICI), a type of cancer therapy that helps the immune system fight tumours, was one of the most significant milestones in cancer treatment in the last decade. While ICI therapy has been used to treat different cancer types, it is not universally effective and relapsed disease occurs. A robust strategy for predicting which patients are likely to respond to ICIs is needed, enabling clinicians to select the best course of treatment for each patient.